Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
accepted:
10
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
In 2018, the French government introduced two mutually exclusive financial incentives to increase etanercept and insulin glargine biosimilar use. The general case redirects 20% of the price difference between the reference product and its biosimilars to hospitals for every biosimilar dispensed in community pharmacies from hospital prescriptions. The experimental case redirects 30% to prescribing clinical units after hospital selection. Adalimumab was added to these incentives in 2019, after its first biosimilar was launched. This retrospective observational study aimed to compare both general and experimental incentives after 19 months to assess the impact of directly incentivizing clinical units for adalimumab biosimilars. The monthly number of adalimumab boxes dispensed in community pharmacies was linked to the corresponding hospital's prescription using IQVIA Xponent data from November 2017 to October 2020. The monthly mean rate of adalimumab biosimilars was compared between incentive groups and subgroups depending on hospitals' prior experience with the etanercept experimental case. General case hospitals had a significantly lower mean biosimilar uptake (16.7% vs 23.2%, p = 0.029) than those included in the experimental case. Twenty-three of the 40 hospitals in the experimental case and ten out of the 91 hospitals studied in the general case had already taken part in the etanercept experiment. Biosimilar uptake was higher, but not statistically significant, for hospitals with prior experience in the adalimumab general case group (p = 0.086). This study confirmed that incentivizing close to physicians was more effective in increasing the biosimilar rate. It also suggested that previous incentive experience positively influenced biosimilar penetration.
Sections du résumé
BACKGROUND
BACKGROUND
In 2018, the French government introduced two mutually exclusive financial incentives to increase etanercept and insulin glargine biosimilar use. The general case redirects 20% of the price difference between the reference product and its biosimilars to hospitals for every biosimilar dispensed in community pharmacies from hospital prescriptions. The experimental case redirects 30% to prescribing clinical units after hospital selection. Adalimumab was added to these incentives in 2019, after its first biosimilar was launched.
OBJECTIVE
OBJECTIVE
This retrospective observational study aimed to compare both general and experimental incentives after 19 months to assess the impact of directly incentivizing clinical units for adalimumab biosimilars.
METHOD
METHODS
The monthly number of adalimumab boxes dispensed in community pharmacies was linked to the corresponding hospital's prescription using IQVIA Xponent data from November 2017 to October 2020. The monthly mean rate of adalimumab biosimilars was compared between incentive groups and subgroups depending on hospitals' prior experience with the etanercept experimental case.
RESULTS
RESULTS
General case hospitals had a significantly lower mean biosimilar uptake (16.7% vs 23.2%, p = 0.029) than those included in the experimental case. Twenty-three of the 40 hospitals in the experimental case and ten out of the 91 hospitals studied in the general case had already taken part in the etanercept experiment. Biosimilar uptake was higher, but not statistically significant, for hospitals with prior experience in the adalimumab general case group (p = 0.086).
CONCLUSIONS
CONCLUSIONS
This study confirmed that incentivizing close to physicians was more effective in increasing the biosimilar rate. It also suggested that previous incentive experience positively influenced biosimilar penetration.
Identifiants
pubmed: 38956007
doi: 10.1007/s41669-024-00505-7
pii: 10.1007/s41669-024-00505-7
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Troein P et al. for IQVIA. The Impact of Biosimilar Competition in Europe 2021. White paper online 2021, Dec. [cited 2022 feb 15]. Available from https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021 .
Beck M, Michel B, Rybarczyk-Vigouret MC, Levêque D, Sordet C, Sibilia J, Velten M. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. MAbs. 2017;9(2):384–91.
doi: 10.1080/19420862.2016.1267087
Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970. https://doi.org/10.3389/fphar.2020.00970 .
Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308.
doi: 10.1080/20016689.2016.1272308
pubmed: 28265349
pmcid: 5328350
IQVIA. Advancing biosimilar sustainability in Europe. 2018, Sept. [cited 2022 dec 7]. IQVIA institute report. Available from https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-biosimilar-sustainability-in-europe .
Chevreul K, Berg Brigham K, Durand-Zaleski I, HernándezQuevedo C. France: health system review [Internet]. Brussels: European Observatory on Health Systems and Policies; 2015 [cited 2021 Jun 17]. Available from: https://www.euro.who.int/__data/assets/pdf_ file/0011/297938/France-HiT.p
Ministère des solidarités et de la santé. CEPS (Comité économique des produits de santé). Accord cadre du 5 mars 2021 entre le CEPS et le LEEM [Internet]. [cited 2023 Jun 10]. Available from: https://sante.gouv.fr/ministere/acteurs/instances-rattachees/comite-economique-des-produits-de-sante-ceps/article/presentation-du-comite-economique-des-produits-de-sante-ceps
Robinson JC, Jarrion Q. Competition from biosimilars drives price reductions for biologics in the French single-payer health system. Health Aff. 2021;40(8):1190–7.
doi: 10.1377/hlthaff.2021.00070
Statista. Principaux produits pharmaceutiques par ventes mondiales 2018. [Internet]. [cited 2023 Jun 10]. Available from: https://fr.statista.com/statistiques/564382/principaux-produits-pharmaceutiques-par-ventes-internationales/
IQVIA. L’analyse mensuelle du marché des médicaments - Pharmastat: La bataille de l’adalimumab. PharmaNews. Mars 2019, no124.
Ministère des solidarités et de la santé, ministère de l’Économie, des finances et de la relance. Arrêté du 12 avril 2022 fixant la liste des groupes biologiques similaires substituables par le pharmacien d'officine et les conditions de substitution et d'information du prescripteur et du patient telles que prévues au 2° de l'article L. 5125-23-2 du code de la santé publique [Internet] JORF n°0088, NOR SSAS2211448A Avril 2022. Available from: https://www.legifrance.gouv.fr/eli/arrete/2022/4/12/SSAS2211448A/jo/texte
Ministère des solidarités et de la santé. Arrêté du 3 août 2018 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville [Internet]. JORF n°0188, NOR SSAS1821431A août, 2018. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000037316661
Ministère des solidarités et de la santé. Arrêté du 12 février 2019 relatif à l'expérimentation pour l'incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville [Internet]. JORF n°0039, NOR SSAS1904496A février 2019. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000038129827
Assurance Maladie. Rapport charges et produits-propositions de l’assurance maladie pour-2019.pdf [Internet]. 2018 Jul [cited 2022 Jun 10]. Available from: https://assurance-maladie.ameli.fr/sites/default/files/2018-07_rapport-propositions-pour-2019_assurance-maladie.pdf
Loi n° 2017-1836 du 30 décembre 2017 de financement de la sécurité sociale pour 2018 [Internet]. JORF n°0305, NOR CPAX1725580L décembre, 2017. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000036339090/ .
Ministère des solidarités et de la santé, ministère de l’action et des comptes publics. Arrêté du 12 avril 2019 fixant la liste des établissements retenus dans le cadre de l’extension au groupe adalimumab de l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. [Internet]. JORF n°0091, NOR SSAS1911171A, Avril 2019. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000038383120
Ministère de la santé et de la prévention, ministère de l'économie, des finances et de la souveraineté industrielle et numérique. Arrêté du 30 août 2022 modifiant l’arrêté du 19 avril 2021 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques délivrés en ville. [Internet]. JORF 0207 NOR SPRS2224973A, aout 2022. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000046264090
Ministère des solidarités et de la santé, ministère de l’action et des comptes publics. Arrêté du 29 mai 2019 relatif à l’efficience et la pertinence de la prescription hospitalière de médicaments biologiques similaires délivrés en ville. [Internet]. JORF n°0130, NOR SSAS1915874A, mai 2019. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000038554643
Tano M, Paubel P, Ribault M, Degrassat-Théas A. What about offering a financial incentive directly to clinical units to encourage the use of biosimilars? Results of a Two-Year National Experiment in France. Appl Health Econ Health Policy. 2023. https://doi.org/10.1007/s40258-023-00812-w . (Epub ahead of print. PMID: 37253898; PMCID: PMC10228890).
doi: 10.1007/s40258-023-00812-w
pubmed: 37253898
pmcid: 10228890
Ministère du travail, de la santé et des solidarités. Expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. [Internet]. [cited 2024 March 25]. Available from : https://sante.gouv.fr/systeme-de-sante/parcours-des-patients-et-des-usagers/article-51-lfss-2018-innovations-organisationnelles-pour-la-transformation-du/les-experimentations/article/experimentation-pour-l-incitation-a-la-prescription-hospitaliere-de-medicaments
ATIH. Open data available from https://hospidiag.atih.sante.fr/
RStudio Team. RStudio: Integrated Development for R [Internet]. RStudio, PBC, Boston, MA. 2020. Available from http://www.rstudio.com/ .
R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2016. Available from: https://www.R-project.org/
Eurostat for European Commission.European Price Statistics. An overview. [Internet] 2018 edition [cited 2024 Apr 15]. Available from: https://ec.europa.eu/eurostat/en/web/products-statistical-books/-/ks-70-07-038 .
Diewert E. (International monetary fund). Consumer Price Index Theory: Chapter 2: Basic Index Number Theory. [Internet]. April 16, 2021. Available from file:///Users/mariontano/Downloads/chapter-1-basic-index-number-theory.pdf
Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, et al. The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in europe: an overview of pricing and national policy measures. Front Pharmacol. 2021;11:591134.
doi: 10.3389/fphar.2020.591134
pubmed: 33519450
pmcid: 7839249
Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? Front Pharmacol [Internet]. 2020. https://doi.org/10.3389/fphar.2020.00970 .
doi: 10.3389/fphar.2020.00970
pubmed: 33708116
pmcid: 7578430
Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between swedish counties influence market dynamics: part 2—biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306.
doi: 10.1007/s40259-019-00346-5
pubmed: 30945206
pmcid: 6533216